Prognostic Value of Semi-Quantitative Metabolic Parameters on [18F]FDG PET/CT in Patients with Diffuse Large B-Cell Lymphoma at Diagnosis
Current Oncology · 01.07.2026 · 33 (7) · 392
DOI: 10.3390/curroncol33070392 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, online erschienen am 01.07.2026. Verfasst von Emanuele Cencini und 11 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
After first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), 20–30% of patients with diffuse large B-cell lymphoma (DLBCL) have relapsed or refractory disease. Semi-quantitative volume parameters on [18F]Fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG PET/CT), performed at diagnosis, could represent variables with prognostic influence. We retrospectively analyzed 53 consecutive patients, treated between 2016 and 2022. Semi-quantitative metabolic parameters, assessed by the software LIFEx, included total metabolic tumor volume (TMTV), total lesion glycolysis (TLG), Dmax and DmaxVox. All cases received R-CHOP/CHOP-like regimens with curative intent. The International Metabolic Prognostic Index (IMPI) was low in 43/53 cases (81.1%). CR was achieved in 49/53 patients (92.4%); 7/53 (13.2%) relapsed after achieving a CR. For the entire cohort, 2-year PFS and OS were 84.9% and 90.6%, respectively, while 5-year PFS and OS were 65.5% and 77.6%, respectively. IPI score, B symptoms, TMTV, Dmax and DmaxVox were associated with reduced PFS in an exploratory univariate analysis. IPI score was the only variable for which we found a significant association with reduced OS. In this exploratory analysis in a small, event-limited population, we suggest the baseline, semi-quantitative metabolic parameters of PET/CT at diagnosis could contribute to defining tumor burden and to predict PFS for DLBCL patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy.
- Unit of Nuclear Medicine, Azienda Ospedaliera Universitaria Senese, 53100 Siena, Italy.
ORCID-Profile: Emanuele Cencini, Anna Sicuranza, Monica Bocchia, Alberto Fabbri
Zitieren
APA
Cencini, E., Orsini, F., Franceschini, M., Fredducci, S., Bello, M., Pacini, E., Bradaschia, M., Sicuranza, A., Carrara, C., Bertelli, P., Bocchia, M., & Fabbri, A. (2026). Prognostic Value of Semi-Quantitative Metabolic Parameters on [18F]FDG PET/CT in Patients with Diffuse Large B-Cell Lymphoma at Diagnosis. Current Oncology, 33(7), 392. https://doi.org/10.3390/curroncol33070392
Vancouver
Cencini E, Orsini F, Franceschini M, Fredducci S, Bello M, Pacini E, et al. Prognostic Value of Semi-Quantitative Metabolic Parameters on [18F]FDG PET/CT in Patients with Diffuse Large B-Cell Lymphoma at Diagnosis. Current Oncology. 2026;33(7):392. doi:10.3390/curroncol33070392
BibTeX
@article{Cencini2026,
author = {Cencini, Emanuele and Orsini, Federica and Franceschini, Marta and Fredducci, Sara and Bello, Mattia and Pacini, Emanuele and Bradaschia, Marcello and Sicuranza, Anna and Carrara, Chiara and Bertelli, Paolo and Bocchia, Monica and Fabbri, Alberto},
title = {Prognostic Value of Semi-Quantitative Metabolic Parameters on [18F]FDG PET/CT in Patients with Diffuse Large B-Cell Lymphoma at Diagnosis},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {7},
pages = {392},
doi = {10.3390/curroncol33070392}
}
EUVIMED